AbbVie Inc.

ABBV ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $61.16B $56.33B $54.32B $58.05B $56.20B $45.80B $33.27B $32.75B
Immunology $30.41B $26.68B $26.14B — — — — —
Neuroscience $10.77B $9.00B $7.72B — — — — —
Oncology $6.66B $6.56B $5.92B — — — — —
Aesthetics $4.86B $5.18B $5.29B — — — — —
Eye Care $2.11B $2.24B $2.42B — — — — —
Other $6.36B $6.68B $6.84B — — — — —
Cost of Revenue $18.20B $16.90B $20.42B $17.41B $17.45B $15.39B $7.44B $7.72B
Gross Profit $42.96B $39.43B $33.90B $40.64B $38.75B $30.42B $25.83B $25.04B
Gross Margin 70.2% 70.0% 62.4% 70.0% 69.0% 66.4% 77.6% 76.4%
Operating Expenses
Research & Development — — — — — — — —
SG&A Expense $14.01B $14.75B $12.87B $15.26B $12.35B $11.30B $6.94B $7.40B
Operating Income $15.08B $9.14B $12.76B $18.12B $17.92B $11.36B $12.98B $6.38B
Operating Margin 24.6% 16.2% 23.5% 31.2% 31.9% 24.8% 39.0% 19.5%
Interest Expense $2.89B $2.81B $2.22B $2.23B $2.42B $2.45B $1.78B $1.35B
Pretax Income $6.60B $3.72B $6.25B $13.48B $12.99B $3.40B $8.43B $5.20B
Income Tax Expense $2.36B $-570.0M $1.38B $1.63B $1.44B $-1.22B $544.0M $-490.0M
Net Income $4.23B $4.28B $4.86B $11.84B $11.54B $4.62B $7.88B $5.69B
Net Margin 6.9% 7.6% 9.0% 20.4% 20.5% 10.1% 23.7% 17.4%
EPS (Basic) $2.37 $2.40 $2.73 $6.65 $6.48 $2.73 $5.30 $3.67
EPS (Diluted) $2.36 $2.39 $2.72 $6.63 $6.45 $2.72 $5.28 $3.66
Shares Outstanding (Basic) 1.77B 1.77B 1.77B 1.77B 1.77B 1.67B 1.48B 1.54B
Shares Outstanding (Diluted) 1.77B 1.77B 1.77B 1.78B 1.78B 1.67B 1.48B 1.55B
Dividends Per Share $6.65 $6.29 $5.99 $5.71 $5.31 $4.84 $4.39 $3.95
← Newer Page 1 of 2 Older →